相似文献
1
Targeting telomerase for cancer therapeutics.
Br J Cancer. 2008 Feb 26;98(4):677-83. doi: 10.1038/sj.bjc.6604209. Epub 2008 Jan 29.
2
Telomerase: a target for cancer therapeutics.
Cancer Cell. 2002 Oct;2(4):257-65. doi: 10.1016/s1535-6108(02)00159-9.
3
Telomerase and cancer therapeutics.
Nat Rev Cancer. 2008 Mar;8(3):167-79. doi: 10.1038/nrc2275.
4
Telomeres and telomerase as targets for anticancer drug development.
Crit Rev Oncol Hematol. 2006 Mar;57(3):191-214. doi: 10.1016/j.critrevonc.2005.08.007.
5
Telomerase regulation: a key to inhibition? (Review).
Int J Oncol. 2013 Nov;43(5):1351-6. doi: 10.3892/ijo.2013.2104. Epub 2013 Sep 16.
6
Novel anticancer therapeutics targeting telomerase.
Cancer Treat Rev. 2013 Aug;39(5):444-56. doi: 10.1016/j.ctrv.2012.06.007. Epub 2012 Jul 26.
7
Targeting telomeres and telomerase.
Biochimie. 2008 Jan;90(1):131-55. doi: 10.1016/j.biochi.2007.07.011. Epub 2007 Jul 24.
8
Telomerase inhibition as cancer therapy.
Cancer Lett. 2003 May 15;194(2):209-19. doi: 10.1016/s0304-3835(02)00708-5.
9
Harnessing telomerase in cancer therapeutics.
Anticancer Agents Med Chem. 2007 Jul;7(4):475-83. doi: 10.2174/187152007781058622.
10
Telomere maintenance as a target for drug discovery.
J Med Chem. 2014 Feb 13;57(3):521-38. doi: 10.1021/jm400528t. Epub 2013 Oct 15.
引用本文的文献
1
Evolutionarily conserved role of telomerase reverse transcriptase in programming the microenvironment via regulation of the cGAS-STING pathway.
Nat Cell Biol. 2025 Aug 6. doi: 10.1038/s41556-025-01706-w.
2
Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma.
Cell Rep. 2025 May 27;44(5):115596. doi: 10.1016/j.celrep.2025.115596. Epub 2025 Apr 19.
3
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.
Int J Mol Sci. 2024 Aug 30;25(17):9463. doi: 10.3390/ijms25179463.
4
Synthesis and Molecular Dynamic Simulation of Novel Cationic and Non-cationic Pyrimidine Derivatives as Potential G-quadruplex-ligands.
Anticancer Agents Med Chem. 2024;24(15):1126-1141. doi: 10.2174/0118715206291797240523112439.
5
P19 a Parthenin Analog Induces Cell Lineage Dependent Apoptotic and Immunomodulatory Signaling in Acute Lymphoid Leukemia Cells.
Int J Mol Cell Med. 2023;12(1):1-17. doi: 10.22088/IJMCM.BUMS.12.1.1.
6
Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins.
J Am Chem Soc. 2023 May 17;145(19):10872-10879. doi: 10.1021/jacs.3c02783. Epub 2023 May 4.
7
Teloxantron inhibits the processivity of telomerase with preferential DNA damage on telomeres.
Cell Death Dis. 2022 Nov 28;13(11):1005. doi: 10.1038/s41419-022-05443-y.
8
New therapeutic strategies based on interference with telomeric DNA synthesis of tumor cells to suppress the growth of tumors.
RSC Adv. 2018 Jul 11;8(44):25001-25007. doi: 10.1039/c8ra02599a. eCollection 2018 Jul 9.
9
Τelomerase inhibitors and activators in aging and cancer: A systematic review.
Mol Med Rep. 2022 May;25(5). doi: 10.3892/mmr.2022.12674. Epub 2022 Mar 10.
10
Cost-Effective Trap qPCR Approach to Evaluate Telomerase Activity: an Important Tool for Aging, Cancer, and Chronic Disease Research.
Clinics (Sao Paulo). 2021 Feb 5;76:e2432. doi: 10.6061/clinics/2021/e2432. eCollection 2021.
本文引用的文献
1
Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity.
Biochimie. 2008 Jan;90(1):13-23. doi: 10.1016/j.biochi.2007.07.025. Epub 2007 Aug 6.
2
Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells.
Drug Discov Today. 2007 Aug;12(15-16):611-21. doi: 10.1016/j.drudis.2007.06.009. Epub 2007 Jul 27.
3
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells.
Stem Cells. 2007 Aug;25(8):1853-61. doi: 10.1634/stemcells.2007-0057. Epub 2007 May 17.
4
Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell.
Regen Med. 2006 Jan;1(1):125-31. doi: 10.2217/17460751.1.1.125.
5
Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Curr Cancer Drug Targets. 2007 Mar;7(2):191-201. doi: 10.2174/156800907780058835.
6
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.
Br J Cancer. 2006 Dec 4;95(11):1474-82. doi: 10.1038/sj.bjc.6603437. Epub 2006 Oct 24.
7
Telomerase therapeutics for cancer: challenges and new directions.
Nat Rev Drug Discov. 2006 Jul;5(7):577-84. doi: 10.1038/nrd2081. Epub 2006 Jun 9.
8
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Cancer Immunol Immunother. 2006 Dec;55(12):1553-64. doi: 10.1007/s00262-006-0145-7. Epub 2006 Feb 21.
9
Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.
Breast Cancer Res Treat. 2006 Mar;96(1):73-81. doi: 10.1007/s10549-005-9043-5. Epub 2005 Dec 1.
10
Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.
Nat Clin Pract Oncol. 2004 Dec;1(2):88-96. doi: 10.1038/ncponc0044.
Zotero 插件
